Pet Pharm Biotech Co., Ltd.

Pet Pharm Biotech Co., Ltd. is a biotechnology company specializing in the development, production, and sale of pharmaceutical products with a focus on molecular imaging medicines and radiopharmaceuticals. Founded in 2011 and headquartered in New Taipei City, Taiwan, the company employs specialized manufacturing processes compliant with PIC/S GMP (Pharmaceutical Inspection Co-operation Scheme, Good Manufacturing Practice) for sterile preparations. Its core product portfolio includes FDG Fludeoxyglucose (F-18) Injection, used primarily for diagnostic imaging in cancer types such as lung, colorectal, and lymphoma, as well as conditions including melanoma, coronary heart disease, and epilepsy. Additional products, such as sodium fluoride injections, serve as contrast agents in bone imaging, and radioactive sodium iodide capsules are indicated for thyroid-related treatments and imaging. Pet Pharm Biotech also engages in developing contrast agents for brain positron tomography and actively pursues innovation in international new drug development. The company predominantly serves the Taiwanese medical market, supporting advanced diagnostics and treatment planning in oncology, neurology, and endocrinology, thereby playing a vital role in Taiwan’s healthcare and pharmaceutical industries.